Integrative Medicine
Cancer treatment has come a long way, but for many patients, the search for options beyond traditional approaches feels urgent. Integrative medicine steps into this space, blending conventional therapies with innovative, non-toxic approaches that aim to target cancer from multiple angles.
Some of the most forward-thinking minds in cancer treatment are challenging conventional approaches, exploring ways to make therapies more precise and less toxic. Dr. Stanislaw Burzynski is known for his work on antineoplaston therapy, a treatment designed to fight cancer at a molecular level. Dr. Thomas Seyfried has spent years studying cancer metabolism, challenging the idea that cancer is purely a genetic disease.
Jane McLelland, a cancer survivor herself, shares practical ways to “starve” cancer using metabolic therapies and repurposed drugs. Meanwhile, physicians like Dr. Akbar Khan offer patients personalized, integrative options.
For those seeking a broader perspective on cancer care, these approaches provide hope—and a fresh way of thinking about treatment.
Our work is independent and has no affiliation with any of these people, but we recognize that their approach aligns with ours. Wishing to help people live as well as possible for as long as possible.
The Burzynski Clinic, established in 1977 by Dr. Stanislaw R. Burzynski, is a cancer treatment center located in Houston, Texas. The clinic provides individualized cancer treatments that concentrate on precision immunotherapy and genetic-specific therapy for each patient’s malignancy.
The physician developed antineoplaston therapy which uses peptides and derivatives for alternative cancer treatment.
The treatment protocols of Dr. Burzynski include the use of Sodium Phenylbutyrate (4PBA). The drug 4PBA breaks down into phenylacetate which shares structural and functional similarities with specific antineoplastons such as AS2-1. This is why 4PBA is often associated with antineoplaston therapy and is sometimes used by his clinic as an alternative treatment.
Dr. Stanislaw Burzynski has fostered a dedicated community of patients and supporters, united in their pursuit of a more holistic approach to cancer care.
Dr. Thomas N. Seyfried is a prominent figure in the field of integrative medicine, particularly known for his research on cancer as a metabolic disease. As a biology professor at Boston College Dr. Seyfried investigates how metabolic therapy offers management solutions for chronic conditions like epilepsy and cancer along with neurodegenerative lipid storage diseases.
His work has reshaped how we understand cancer, inspiring both researchers and patients to explore metabolic-based treatment strategies. Dr. Seyfried asserts that cancer originates as a metabolic disease because it develops from energy production disruptions at the cellular level caused mainly by mitochondrial dysfunction. This perspective suggests that targeting cancer metabolism could lead to non-toxic therapeutic strategies.
He has authored over 150 peer-reviewed publications. His book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer” provides extensive evidence supporting the metabolic theory of cancer.
A YouTube channel titled “Dr. Thomas Seyfried Charity” has various interviews, lectures, and discussions featuring Dr. Seyfried’s work and insights into cancer metabolism and integrative treatment approaches.
The passionate support he’s garnered speaks to the impact of his research on countless individuals and suggests that this “metabolic revolution” in cancer care will continue to grow.
“How to Starve Cancer” is dedicated to sharing the insights and methodologies of Jane McLelland, a former physiotherapist who developed a unique approach to combating cancer based on her personal experiences as a survivor.
She shares detailed background information about her personal journey and how she created cancer-starving methods.
Jane McLelland’s work provides integrative medicine enthusiasts with insights into using metabolic strategies together with repurposed drugs to enhance standard cancer treatments. Her focus on cancer metabolism supports integrative medicine principles which combine traditional treatment methods with alternative therapies for holistic patient care.
She actively engages with this community by sharing insights, research updates, and personal stories to empower patients in their healing journeys.
Medicor Cancer Centres, established in 2006 by Dr. Akbar Khan, is a Toronto-based medical facility specializing in integrative, non-toxic cancer therapies. The center merges traditional allopathic cancer treatments with naturopathic methods to deliver personalized healthcare for cancer patients.
Various media outlets have featured Dr. Khan and Medicor together with their published contributions to peer-reviewed medical journals demonstrate their dedication to developing non-toxic cancer treatments.
Medicor Cancer Centres demonstrates its integrative oncology model by merging traditional treatments with alternative methods to deliver customized, non-toxic cancer therapy options. Through their dedication to innovative therapies and patient-centred care they establish themselves as leaders within integrative medicine.
Dr. Akbar Khan has built a community of patients and practitioners exploring innovative cancer treatments, sharing knowledge, and supporting alternative and integrative therapies like Sodium phenylbutyrate.
As a former physician at the Cross Cancer Institute in Edmonton, Alberta, Dr. Makis contributed to one of North America’s largest targeted radionuclide therapy programs. His expertise in theranostics—a combination of therapy and diagnostics—has helped shape more precise, individualized cancer treatment approaches.
Dr. Makis has authored over 100 peer-reviewed publications, covering nuclear medicine, cancer imaging, and non-invasive treatment techniques. He is an advocate for early cancer detection, patient-centered care, and innovative treatment protocols aimed at improving long-term survival outcomes.
Through his research and public advocacy, Dr. Makis has gained a following among those seeking alternative diagnostic methods and metabolic cancer treatments, bridging the gap between conventional oncology and emerging precision medicine approaches.
